AVXL gets patent to use drug for anxiety, insomnia. Not only is this a new application, but it extends patent protection to 2037

https://finance.yahoo.com/news/anavex-life-sc...00136.html

Quote:

---

today announced that the United States Patent and Trademark Office (USPTO) granted U.S. Patent No. 11,813,242 entitled “A2-73 AS A THERAPEUTIC FOR INSOMNIA, ANXIETY, AND AGITATION”. This patent expands Anavex’s existing patent coverage of ANAVEX®2-73 (blarcamesine), including U.S. Patent No. 11,337,953 to cover Anavex’s leading drug candidate, ANAVEX®2-73 (blarcamesine), ANAVEX®1-41 and ANAVEX®19-144, for treating insomnia, anxiety or agitation.

Insomnia-related costs in the U.S. have been estimated in 2020 to exceed $100 billion per year.1 The economic burden of anxiety in the U.S. was estimated in 2019 to be over $46.4 billion.2 The total incremental cost of just institutionalization of Alzheimer’s disease patients associated with agitation was estimated in 2019 at $4.3 billion in the U.S.3

This newest patent is expected to remain in force at least until July 2037, not including any patent term extension. Together with Anavex U.S. Patent No. 11,337,953, which is expected to remain in force at least until 2038, not including any patent term extension, the two patents provide extensive coverage of ANAVEX®2-73 (blarcamesine) for use in treating either insomnia or anxiety, used alone or in combination with ANAVEX®19-144 or ANAVEX®1-41.

---